Research Progress of SN38 Drug Delivery System in Cancer Treatment

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2024 Jan 31

PMID 38293612

Authors

Qing-Rui Qi

Huan Tian

Bao-Sen Yue

Bing-Tao Zhai

Feng Zhao

Affiliations

Soon will be listed here.

Abstract

The active metabolite of irinotecan (CPT-11), 7-ethyl-10-hydroxycamptothecin (SN38), is 100-1000 times more active than CPT-11 and has shown inhibitory effects on a range of cancer cells, including those from the rectal, small cell lung, breast, esophageal, uterine, and ovarian malignancies. Despite SN38's potent anticancer properties, its hydrophobicity and pH instability have caused substantial side effects and anticancer activity loss, which make it difficult to use in clinical settings. To solve the above problems, the construction of SN38-based drug delivery systems is one of the most feasible methods to improve drug solubility, enhance drug stability, increase drug targeting ability, improve drug bioavailability, enhance therapeutic efficacy and reduce adverse drug reactions. Therefore, based on the targeting mechanism of drug delivery systems, this paper reviews SN38 drug delivery systems, including polymeric micelles, liposomal nanoparticles, polymeric nanoparticles, protein nanoparticles, conjugated drug delivery systems targeted by aptamers and ligands, antibody-drug couplings, magnetic targeting, photosensitive targeting, redox-sensitive and multi-stimulus-responsive drug delivery systems, and co-loaded drug delivery systems. The focus of this review is on nanocarrier-based SN38 drug delivery systems. We hope to provide a reference for the clinical translation and application of novel SN38 medications.

Citing Articles

Understanding the Toxicity Profile of Approved ADCs.

Ballestin P, Lopez de Sa A, Diaz-Tejeiro C, Paniagua-Herranz L, Sanvicente A, Lopez-Cade I Pharmaceutics. 2025; 17(2).

PMID: 40006625 PMC: 11858992. DOI: 10.3390/pharmaceutics17020258.

Novel Cyclic Peptide-Drug Conjugate P6-SN38 Toward Targeted Treatment of EGFR Overexpressed Non-Small Cell Lung Cancer.

Bazylevich A, Miller A, Tkachenko I, Merlani M, Patsenker L, Gellerman G Pharmaceutics. 2025; 16(12.

PMID: 39771591 PMC: 11676734. DOI: 10.3390/pharmaceutics16121613.

Novel Strategies for Tumor Treatment: Harnessing ROS-Inducing Active Ingredients from Traditional Chinese Medicine Through Multifunctional Nanoformulations.

Zhang Z, Li M, Zhang X, Zhou F Int J Nanomedicine. 2024; 19:9659-9688.

PMID: 39309188 PMC: 11416109. DOI: 10.2147/IJN.S479212.

Advances on Delivery System of Active Ingredients of Dried Toad Skin and Toad Venom.

Zhang D, Zhai B, Sun J, Cheng J, Zhang X, Guo D Int J Nanomedicine. 2024; 19:7273-7305.

PMID: 39050871 PMC: 11268768. DOI: 10.2147/IJN.S469742.

Investigating the Impact of SN-38 on Mouse Brain Metabolism Based on Metabolomics.

Zhu X, Huang Y, Ding J, Liu J, Cui C, Han G Drug Des Devel Ther. 2024; 18:2435-2447.

PMID: 38915864 PMC: 11195675. DOI: 10.2147/DDDT.S457698.

References

Heist R, Guarino M, Masters G, Purcell W, Starodub A, Horn L . Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. J Clin Oncol. 2017; 35(24):2790-2797. DOI: 10.1200/JCO.2016.72.1894. View

Yang C, Xia A, Du C, Hu M, Gong Y, Tian R . Discovery of highly potent and selective 7-ethyl-10-hydroxycamptothecin-glucose conjugates as potential anti-colorectal cancer agents. Front Pharmacol. 2022; 13:1014854. PMC: 9726873. DOI: 10.3389/fphar.2022.1014854. View

Syed Y . Sacituzumab Govitecan: First Approval. Drugs. 2020; 80(10):1019-1025. PMC: 7288263. DOI: 10.1007/s40265-020-01337-5. View

Nogueira E, Gomes A, Preto A, Cavaco-Paulo A . Design of liposomal formulations for cell targeting. Colloids Surf B Biointerfaces. 2015; 136:514-26. DOI: 10.1016/j.colsurfb.2015.09.034. View

Hafeez U, Parakh S, Gan H, Scott A . Antibody-Drug Conjugates for Cancer Therapy. Molecules. 2020; 25(20). PMC: 7587605. DOI: 10.3390/molecules25204764. View

Liu H, Lu H, Liao L, Zhang X, Gong T, Zhang Z . Lipid nanoparticles loaded with 7-ethyl-10-hydroxycamptothecin-phospholipid complex: in vitro and in vivo studies. Drug Deliv. 2014; 22(6):701-9. DOI: 10.3109/10717544.2014.895069. View

Kesari M, Gaopande V, Joshi A, Babanagare S, Gogate B, Khadilkar A . Immunohistochemical study of MUC1, MUC2 and MUC5AC in colorectal carcinoma and review of literature. Indian J Gastroenterol. 2015; 34(1):63-7. DOI: 10.1007/s12664-015-0534-y. View

Fang Y, Chuang C, Wu Y, Lin H, Lu Y . SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study. Int J Nanomedicine. 2018; 13:2789-2802. PMC: 5955381. DOI: 10.2147/IJN.S158426. View

Cheng G, Zhang X, Chen Y, Lee R, Wang J, Yao J . Anticancer activity of polymeric nanoparticles containing linoleic acid-SN38 (LA-SN38) conjugate in a murine model of colorectal cancer. Colloids Surf B Biointerfaces. 2019; 181:822-829. DOI: 10.1016/j.colsurfb.2019.06.020. View

10.

Kurita A, Kado S, Kaneda N, Onoue M, Hashimoto S, Yokokura T . Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion. Cancer Chemother Pharmacol. 2003; 52(5):349-60. DOI: 10.1007/s00280-003-0682-0. View

11.

Sepehri N, Rouhani H, Ghanbarpour A, Gharghabi M, Tavassolian F, Amini M . Human serum albumin conjugates of 7-ethyl-10-hydroxycamptothecin (SN38) for cancer treatment. Biomed Res Int. 2014; 2014:963507. PMC: 4033423. DOI: 10.1155/2014/963507. View

12.

Nawaz F, Kipreos E . Emerging roles for folate receptor FOLR1 in signaling and cancer. Trends Endocrinol Metab. 2022; 33(3):159-174. PMC: 8923831. DOI: 10.1016/j.tem.2021.12.003. View

13.

Talukdar A, Kundu B, Sarkar D, Goon S, Mondal M . Topoisomerase I inhibitors: Challenges, progress and the road ahead. Eur J Med Chem. 2022; 236:114304. DOI: 10.1016/j.ejmech.2022.114304. View

14.

Tsai M, Peng C, Yang S, Shieh M . Photothermal, Targeting, Theranostic Near-Infrared Nanoagent with SN38 against Colorectal Cancer for Chemothermal Therapy. Mol Pharm. 2017; 14(8):2766-2780. DOI: 10.1021/acs.molpharmaceut.7b00315. View

15.

Chen J, Zhou L, Wang C, Sun Y, Lu Y, Li R . A multifunctional SN38-conjugated nanosystem for defeating myelosuppression and diarrhea induced by irinotecan in esophageal cancer. Nanoscale. 2020; 12(41):21234-21247. DOI: 10.1039/d0nr06266a. View

16.

Duan K, Zhang X, Tang X, Yu J, Liu S, Wang D . Fabrication of cationic nanomicelle from chitosan-graft-polycaprolactone as the carrier of 7-ethyl-10-hydroxy-camptothecin. Colloids Surf B Biointerfaces. 2010; 76(2):475-82. DOI: 10.1016/j.colsurfb.2009.12.007. View

17.

Meyer-Losic F, Nicolazzi C, Quinonero J, Ribes F, Michel M, Dubois V . DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies. Clin Cancer Res. 2008; 14(7):2145-53. DOI: 10.1158/1078-0432.CCR-07-4580. View

18.

Ashrafizadeh M, Delfi M, Zarrabi A, Bigham A, Sharifi E, Rabiee N . Stimuli-responsive liposomal nanoformulations in cancer therapy: Pre-clinical & clinical approaches. J Control Release. 2022; 351:50-80. DOI: 10.1016/j.jconrel.2022.08.001. View

19.

Sohail M, Guo W, Li Z, Xu H, Zhao F, Chen D . Nanocarrier-based Drug Delivery System for Cancer Therapeutics: A Review of the Last Decade. Curr Med Chem. 2020; 28(19):3753-3772. DOI: 10.2174/0929867327666201005111722. View

20.

Park J, Hong K, Kirpotin D, Colbern G, Shalaby R, Baselga J . Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res. 2002; 8(4):1172-81. View